Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria

by Nicholas J. White, Tran T. Duong, Chirapong Uthaisin et al.
N Engl J Med 2016; 375:1152-1160, September 22, 2016

9 pp. 283 kB
http://www.nejm.org/doi/pdf/10.1056/NEJMoa1602250image-009

Expanding artemisinin resistance and worsening partner-drug resistance in Southeast Asia threaten the global control of Plasmodium falciparum malaria. New drugs are needed. KAF156 represents a new class of antimalarial agents (imidazolopiperazines).The authors conclude that KAF156 showed antimalarial activity without evident safety concerns in a small number of adults with uncomplicated P. vivax or P. falciparum malaria.

(Visited 32 times, 1 visits today)
This entry was posted in Essential Medicines, General, Malaria. Bookmark the permalink.